RiverVest Venture Management’s OnKure Therapeutics OKUR Stock Holding History

RiverVest Venture Management’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.31M	Hold	253,422	–	–	63%	1
2024 Q2	$3.83M	Hold	253,422	–	–	56.07%	1
2024 Q1	$4.21M	Hold	253,422	–	–	51.67%	1
2023 Q4	$4.05M	Hold	253,422	–	–	14.95%	3
2023 Q3	$19.3M	Hold	253,422	–	–	47.73%	1
2023 Q2	$16.6M	Buy	253,422 +12,500	+5%	+$1.01M	18.44%	3
2023 Q1	$14.4M	Hold	240,922	–	–	16.67%	3
2022 Q4	$5.61M	Hold	240,922	–	–	6.55%	3
2022 Q3	$8.07M	Hold	240,922	–	–	9.37%	3
2022 Q2	$6.38M	Hold	240,922	–	–	9.38%	3
2022 Q1	$7.08M	Hold	240,922	–	–	7.27%	4
2021 Q4	$20.6M	Hold	240,922	–	–	14.7%	4
2021 Q3	$17.9M	Hold	240,922	–	–	3.01%	3
2021 Q2	$22.5M	Buy	+240,922	New	+$26.9M	4.39%	4

Other funds holding OKUR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RiverVest Venture Management's OKUR Position: Q3 2024 in Review

RiverVest Venture Management held its OnKure Therapeutics (OKUR) position steady in Q3 2024 at 253,422 shares worth $4.31M. The position accounts for 63% of the portfolio, ranked #1.

RiverVest Venture Management first reported a position in OKUR in Q2 2021 and has held it in 14 quarters since. The position peaked at $22.5M in Q2 2021. 51 funds tracked by Wall St. Rank hold OKUR as of Q3 2024.

RiverVest Venture Management held 253,422 shares of OnKure Therapeutics worth $4.31M as of Q3 2024.
RiverVest Venture Management left its OnKure Therapeutics share count unchanged in Q3 2024.
OnKure Therapeutics made up 63% of RiverVest Venture Management's portfolio in Q3 2024, its #1 holding.
RiverVest Venture Management first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 14 quarters since.
RiverVest Venture Management's OnKure Therapeutics position peaked at $22.5M in Q2 2021.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2024.

Based on RiverVest Venture Management's 13F filing for Q3 2024, filed 30 Oct 2024.